NeoGenomics Stock Forecast, Price & News

NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

Is NeoGenomics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NeoGenomics stock.
View analyst ratings for NeoGenomics or view top-rated stocks.

How has NeoGenomics' stock been impacted by COVID-19?

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NEO shares have increased by 38.3% and is now trading at $34.26.
View which stocks have been most impacted by COVID-19.

Are investors shorting NeoGenomics?

NeoGenomics saw a decrease in short interest in October. As of October 15th, there was short interest totaling 6,080,000 shares, a decrease of 18.1% from the September 30th total of 7,420,000 shares. Based on an average trading volume of 894,900 shares, the short-interest ratio is currently 6.8 days. Currently, 5.2% of the shares of the stock are sold short.
View NeoGenomics' Short Interest.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for NeoGenomics.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The medical research company had revenue of $121.30 million for the quarter, compared to the consensus estimate of $125.09 million. NeoGenomics had a net margin of 10.08% and a negative trailing twelve-month return on equity of 1.33%. The company's quarterly revenue was down 3.3% compared to the same quarter last year. During the same period last year, the company earned $0.04 EPS.
View NeoGenomics' earnings history.

How often does NeoGenomics pay dividends? What is the dividend yield for NeoGenomics?

NeoGenomics declared a dividend on Tuesday, December 15th. Stockholders of record on Friday, December 18th will be given a dividend of $0.40 per share on Wednesday, December 30th. This represents a yield of 3.13%. The ex-dividend date is Thursday, December 17th.
View NeoGenomics' dividend history.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its FY 2021 earnings guidance on Thursday, November, 18th. The company provided EPS guidance of $-0.290-$-0.250 for the period, compared to the Thomson Reuters consensus estimate of $-0.210. The company issued revenue guidance of $482.50 million-$487.50 million, compared to the consensus revenue estimate of $497.53 million.

What price target have analysts set for NEO?

10 brokerages have issued 1-year price targets for NeoGenomics' stock. Their forecasts range from $45.00 to $65.00. On average, they expect NeoGenomics' share price to reach $54.89 in the next twelve months. This suggests a possible upside of 60.2% from the stock's current price.
View analysts' price targets for NeoGenomics or view top-rated stocks among Wall Street analysts.

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the following people:

• Mark Mallon, Chief Executive Officer & Director
• George A. Cardoza, President & Chief Operating Officer-Lab Operations (LinkedIn Profile)
• Kathryn B. McKenzie, Chief Financial Officer
• Steven A. Ross, Chief Information Officer & Vice President
• John Mooney, Chief Technology Officer

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics CEO Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among NeoGenomics' employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of NeoGenomics' key competitors?

Some companies that are related to NeoGenomics include Molina Healthcare (MOH), PPD (PPD), Teladoc Health (TDOC), GoodRx (GDRX), Carl Zeiss Meditec (AFX), Repligen (RGEN), BioMarin Pharmaceutical (BMRN), Fresenius Medical Care AG & Co. KGaA (FME), Masimo (MASI), Novavax (NVAX), Incyte (INCY), Viatris (VTRS), ICON Public (ICLR), Exact Sciences (EXAS) and Abiomed (ABMD).
View all of NEO's competitors.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (6.16%), Artisan Partners Limited Partnership (5.64%), Janus Henderson Group PLC (3.55%), Macquarie Group Ltd. (1.66%), Geode Capital Management LLC (1.66%) and Kopp Family Office LLC (1.45%). Company insiders that own NeoGenomics stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends for NeoGenomics.

Which institutional investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Blue Water Life Science Advisors LLC, Bellevue Group AG, Kopp Family Office LLC, Jennison Associates LLC, Tygh Capital Management Inc., Granahan Investment Management Inc. MA, Russell Investments Group Ltd., and Janus Henderson Group PLC. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lawrence Martin Weiss, Robert J Shovlin, Steven C Jones, and William Bonello.
View insider buying and selling activity for NeoGenomics or view top insider-selling stocks.

Which institutional investors are buying NeoGenomics stock?

NEO stock was acquired by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Wellington Management Group LLP, Macquarie Group Ltd., Schroder Investment Management Group, Bank Julius Baer & Co. Ltd Zurich, Dimensional Fund Advisors LP, Pura Vida Investments LLC, and BioImpact Capital LLC.
View insider buying and selling activity for NeoGenomics or or view top insider-buying stocks.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $34.26.

How much money does NeoGenomics make?

NeoGenomics has a market capitalization of $4.22 billion and generates $444.45 million in revenue each year. The medical research company earns $4.17 million in net income (profit) each year or $0.36 on an earnings per share basis.

How many employees does NeoGenomics have?

NeoGenomics employs 1,700 workers across the globe.

What is NeoGenomics' official website?

The official website for NeoGenomics is www.neogenomics.com.

Where are NeoGenomics' headquarters?

NeoGenomics is headquartered at 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at (239) 768-0600, via email at [email protected], or via fax at 239-690-4237.